Novel TIM-3 Antibody Sabatolimab Plus Decitabine or Azacitidine for High- or Very High–Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
American Journal of Hematology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM-3 antibody, in combination with decitabine or azacitidine in high- or very high-risk myelodysplastic syndromes
Am. J. Hematol 2023 Nov 22;[EPub Ahead of Print], AM Brunner, J Esteve, K Porkka, S Knapper, E Traer, S Scholl, G Garcia-Manero, N Vey, M Wermke, JJWM Janssen, R Narayan, S Fleming, S Loo, N Tovar, M Kontro, OG Ottmann, P Naidu, H Sun, M Han, R White, N Zhang, A Mohammed, CA Sabatos-Peyton, DP Steensma, ML Rinne, UM Borate, AH WeiFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.